Research letter
Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review

https://doi.org/10.1016/j.jaad.2018.12.017Get rights and content

First page preview

First page preview
Click to open first page preview

References (3)

There are more references available in the full text version of this article.

Cited by (0)

Funding sources: None.

Conflicts of interest: Dr Rosmarin consulted or served on the speakers' bureau for Abbvie, Dermavant, Lilly, Novartis, Janssen, Regeneron, Sanofi, Pfizer, and Celgene. All other authors have no conflicts of interest to disclose.

View full text